Literature DB >> 2919937

Reassessment of indications for digoxin. Are patients being withdrawn?

C A Sueta1, T S Carey, C K Burnett.   

Abstract

Several studies have shown that the majority of patients receiving digoxin can be successfully withdrawn. A medical record review was conducted to determine whether, in practice, patients were being withdrawn from digoxin. Original indications for digoxin therapy in 163 outpatients were as follows: congestive heart failure (CHF), 50%; supraventricular tachycardia (SVT), 23%; CHF and SVT, 10%; and unknown/unclear, 17%. One third of these patients were withdrawn during the 3.5-year study, and 79% remained stable, off digoxin. The most significant predictor of withdrawal was chart indication of reassessment of the need for digoxin. The majority of the patients (68%) were reassessed, and of these, almost half were withdrawn. Physicians appear to be reassessing the need for digoxin therapy, resulting in higher withdrawal rates than previously reported. Results suggest that patients with unclear original indications, a onetime indication, or without clinical evidence of CHF or SVT can be successfully withdrawn.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2919937

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

1.  The effect of prescription size on acquisition of maintenance medications.

Authors:  J F Steiner; L J Robbins; S C Roth; W S Hammond
Journal:  J Gen Intern Med       Date:  1993-06       Impact factor: 5.128

Review 2.  Digoxin toxicity in the aged. Characterising and avoiding the problem.

Authors:  A P Passmore; G D Johnston
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

3.  Incidence of digoxin toxicity in outpatients.

Authors:  J F Steiner; L J Robbins; K E Hammermeister; S C Roth; W S Hammond
Journal:  West J Med       Date:  1994-11

Review 4.  The management of heart failure: a matter of definition?

Authors:  A Harley
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.